Punit Dhillon Biography and Net Worth

CEO of Skye Bioscience

Mr. Dhillon has been the President and Chief Executive Officer of Skye Bioscience since 2020. He has a 20-year track record as an executive and investor in the life sciences industry.

Focusing on early-stage biotechs from start-up through clinical proof-of-concept, he has raised more than $500 million in capital and established multiple pharmaceutical partnerships. At Skye he led the strategic acquisition of a novel peripheral CB1 inhibitor for obesity and other metabolic diseases, attracted specialist life science investors, and built out an expert board and management team. Mr. Dhillon was previously the co-founder and former CEO of OncoSec Medical, a developer of cancer immunotherapies and established collaborations with Merck and Genentech.

Prior to Skye he was a managing director of a private San Diego-based pharmaceutical company where he launched an Asia-focused licensing business unit evaluating opportunities in Korea, China, Japan, and the US, and completed a partnership with BMS. He was formerly a director of the Emerald group of companies with responsibility for private equity investments, operations and business development. As Vice President, Finance and Operations, at Inovio Pharmaceuticals he completed licensing deals with Merck, Wyeth (now Pfizer) and Roche. Punit holds a BA (Honors) in political science and a minor in business administration from Simon Fraser University.

What is Punit Dhillon's net worth?: The estimated net worth of Punit Dhillon is at least $85.05 thousand as of November 15th, 2024. Dhillon owns 51,546 shares of Skye Bioscience stock worth more than $85,051 as of October 7th. This net worth estimate does not reflect any other investments that Dhillon may own. Learn More about Punit Dhillon's net worth.
How do I contact Punit Dhillon?: The corporate mailing address for Dhillon and other Skye Bioscience executives is 11250 EL Camino Real, Suite 100, San Diego, CA, 92130. Skye Bioscience can also be reached via phone at 858-410-0266 and via email at [email protected]. Learn More on Punit Dhillon's contact information.
Has Punit Dhillon been buying or selling shares of Skye Bioscience?: Punit Dhillon has not been actively trading shares of Skye Bioscience during the last quarter. Most recently, Punit Dhillon sold 10,318 shares of the business's stock in a transaction on Monday, November 18th. The shares were sold at an average price of $39.92, for a transaction totalling $411,894.56. Following the completion of the sale, the chief executive officer now directly owns 41,227 shares of the company's stock, valued at $1,645,781.84. Learn More on Punit Dhillon's trading history.
Who are Skye Bioscience's active insiders?: Skye Bioscience's insider roster includes Punit Dhillon (CEO), and Andrew Schwab (Director). Learn More on Skye Bioscience's active insiders.
Are insiders buying or selling shares of Skye Bioscience?: In the last twelve months, insiders at the sold shares 12 times. They sold a total of 457,900 shares worth more than $889,198.46. The most recent insider tranaction occured on September, 23rd when Director Andrew J. Schwab sold 119,379 shares worth more than $192,200.19. Insiders at Skye Bioscience own 6.2% of the company. Learn More about insider trades at Skye Bioscience.
Information on this page was last updated on 9/23/2026.

Punit Dhillon Insider Trading History at Skye Bioscience

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/18/2024	Sell	10,318	$39.92	$411,894.56	41,227
11/15/2024	Sell	45	$44.40	$1,998.00	51,546

Punit Dhillon Buying and Selling Activity at Skye Bioscience

Skye Bioscience Company Overview

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Today's Range

Now: $1.65

$1.62

$1.75

50 Day Range

MA: $2.57

$1.57

$4.92

2 Week Range

Now: $1.65

$1.50

$14.51

Volume

55,684 shs

Average Volume

61,517 shs

Market Capitalization

$7.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.86